Target General Information
Target ID	T63505
Target Name	Tyrosine-protein kinase ABL1(ABL1)
Gene Name	ABL1
Species	Homo sapiens
UniProt ID	ABL1_HUMAN
Sequence	MLEICLKLVGCKSKKGLSSSSSCYLEEALQRPVASDFEPQGLSEAARWNSKENLLAGPSE NDPNLFVALYDFVASGDNTLSITKGEKLRVLGYNHNGEWCEAQTKNGQGWVPSNYITPVN SLEKHSWYHGPVSRNAAEYLLSSGINGSFLVRESESSPGQRSISLRYEGRVYHYRINTAS DGKLYVSSESRFNTLAELVHHHSTVADGLITTLHYPAPKRNKPTVYGVSPNYDKWEMERT DITMKHKLGGGQYGEVYEGVWKKYSLTVAVKTLKEDTMEVEEFLKEAAVMKEIKHPNLVQ LLGVCTREPPFYIITEFMTYGNLLDYLRECNRQEVNAVVLLYMATQISSAMEYLEKKNFI HRDLAARNCLVGENHLVKVADFGLSRLMTGDTYTAHAGAKFPIKWTAPESLAYNKFSIKS DVWAFGVLLWEIATYGMSPYPGIDLSQVYELLEKDYRMERPEGCPEKVYELMRACWQWNP SDRPSFAEIHQAFETMFQESSISDEVEKELGKQGVRGAVSTLLQAPELPTKTRTSRRAAE HRDTTDVPEMPHSKGQGESDPLDHEPAVSPLLPRKERGPPEGGLNEDERLLPKDKKTNLF SALIKKKKKTAPTPPKRSSSFREMDGQPERRGAGEEEGRDISNGALAFTPLDTADPAKSP KPSNGAGVPNGALRESGGSGFRSPHLWKKSSTLTSSRLATGEEEGGGSSSKRFLRSCSAS CVPHGAKDTEWRSVTLPRDLQSTGRQFDSSTFGGHKSEKPALPRKRAGENRSDQVTRGTV TPPPRLVKKNEEAADEVFKDIMESSPGSSPPNLTPKPLRRQVTVAPASGLPHKEEAGKGS ALGTPAAAEPVTPTSKAGSGAPGGTSKGPAEESRVRRHKHSSESPGRDKGKLSRLKPAPP PPPAASAGKAGGKPSQSPSQEAAGEAVLGAKTKATSLVDAVNSDAAKPSQPGEGLKKPVL PATPKPQSAKPSGTPISPAPVPSTLPSASSALAGDQPSSTAFIPLISTRVSLRKTRQPPE RIASGAITKGVVLDSTEALCLAISRNSEQMASHSAVLEAGKNLYTFCVSYVDSIQQMRNK FAFREAINKLENNLRELQICPATAGSGPAATQDFSKLLSSVKEISDIVQR [Homo sap iens]
Drug and Corresponding Resistance Mutations
Mutation Info	Missense: A344V
Drugs	Drug Name Imatinib Drug Info [14] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia
Mutation Info	Missense: A350V
Drugs	Drug Name Imatinib Drug Info [14] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia
Mutation Info	Missense: A365V
Drugs	Drug Name Imatinib Drug Info [14] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia
Mutation Info	Missense: A366G
Drugs	Drug Name Imatinib Drug Info [14] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia
Mutation Info	Missense: A380T
Drugs	Drug Name Imatinib Drug Info [14] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia
Mutation Info	Missense: A397P
Drugs	Drug Name Imatinib Drug Info [3] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia Mutation Prevalence 1 out of 77 patients
Mutation Info	Missense: A399T
Drugs	Drug Name Imatinib Drug Info [15] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia
	Drug Name Type I TKIs Drug Info [42]
Mutation Info	Missense: A433T
Drugs	Drug Name Imatinib Drug Info [1], [20], [14] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia Mutation Prevalence 1 out of 94 patients
Mutation Info	Missense: D276A
Drugs	Drug Name Imatinib Drug Info [7] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia Mutation Prevalence 38 out of 45 patients
Mutation Info	Missense: D276G
Drugs	Drug Name Imatinib Drug Info [11] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia Mutation Prevalence 16 out of 49 patients in all ABL mutations
	Drug Name Type I TKIs Drug Info [41]
Mutation Info	Missense: D276N
Drugs	Drug Name Imatinib Drug Info [24] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia
Mutation Info	Missense: D363Y
Drugs	Drug Name Imatinib Drug Info [14] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia
Mutation Info	Missense: D444Y
Drugs	Drug Name Dasatinib Drug Info [36] Targeted Disease Leukemia
Mutation Info	Missense: D482V
Drugs	Drug Name Imatinib Drug Info [2] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia Mutation Prevalence 4 out of 53 patients
Mutation Info	Missense: E255K
Drugs	Drug Name Imatinib Drug Info [1] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia Mutation Prevalence 4 out of 94 patients
	Drug Name Nilotinib Drug Info [20], [14] Targeted Disease Leukemia Mutation Prevalence 2 out of 21 patients
	Drug Name Dasatinib Drug Info [36], [20], [34] Targeted Disease Leukemia Mutation Prevalence 1 out of 21 patients
Mutation Info	Missense: E255V
Drugs	Drug Name Imatinib Drug Info [1] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia Mutation Prevalence 3 out of 94 patients
	Drug Name Nilotinib Drug Info [20], [14] Targeted Disease Leukemia Mutation Prevalence 1 out of 21 patients
	Drug Name Type I TKIs Drug Info [42]
Mutation Info	Missense: E258D
Drugs	Drug Name Imatinib Drug Info [14] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia
Mutation Info	Missense: E275K
Drugs	Drug Name Imatinib Drug Info [14], [28] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia
Mutation Info	Missense: E275Q
Drugs	Drug Name Imatinib Drug Info [14] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia
Mutation Info	Missense: E279A
Drugs	Drug Name Imatinib Drug Info [24] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia
Mutation Info	Missense: E279K
Drugs	Drug Name Imatinib Drug Info [14], [27] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia
Mutation Info	Missense: E279Y
Drugs	Drug Name Imatinib Drug Info [19] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia
Mutation Info	Missense: E279Z
Drugs	Drug Name Imatinib Drug Info [2] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia Mutation Prevalence 1 out of 53 patients
Mutation Info	Missense: E282G
Drugs	Drug Name Imatinib Drug Info [2] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia Mutation Prevalence 2 out of 53 patients
Mutation Info	Missense: E282K
Drugs	Drug Name Type I TKIs Drug Info [42]
Mutation Info	Missense: E292Q
Drugs	Drug Name Imatinib Drug Info [14] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia
Mutation Info	Missense: E292V
Drugs	Drug Name Imatinib Drug Info [1], [2], [14] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia Mutation Prevalence 1 out of 94 patients
Mutation Info	Missense: E352D
Drugs	Drug Name Imatinib Drug Info [2] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia Mutation Prevalence 1 out of 53 patients
Mutation Info	Missense: E352G
Drugs	Drug Name Imatinib Drug Info [2] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia Mutation Prevalence 1 out of 53 patients
Mutation Info	Missense: E355?
Drugs	Drug Name Imatinib Drug Info [19] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia
Mutation Info	Missense: E355A
Drugs	Drug Name Imatinib Drug Info [1], [14], [21] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia Mutation Prevalence 2 out of 94 patients
Mutation Info	Missense: E355D
Drugs	Drug Name Imatinib Drug Info [14] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia
Mutation Info	Missense: E355G
Drugs	Drug Name Imatinib Drug Info [4] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia Mutation Prevalence 7 out of 17 patients
	Drug Name Dasatinib Drug Info [35], [36] Targeted Disease Leukemia
Mutation Info	Missense: E373K
Drugs	Drug Name Imatinib Drug Info [14] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia
Mutation Info	Missense: E450?
Drugs	Drug Name Imatinib Drug Info [19] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia
Mutation Info	Missense: E450A
Drugs	Drug Name Imatinib Drug Info [12], [19], [14] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia Mutation Prevalence 1 out of 62 patients
Mutation Info	Missense: E450G
Drugs	Drug Name Imatinib Drug Info [12] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia Mutation Prevalence 1 out of 62 patients
Mutation Info	Missense: E450K
Drugs	Drug Name Imatinib Drug Info [25], [14] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia Mutation Prevalence 1 out of 55 patients
Mutation Info	Missense: E450V
Drugs	Drug Name Imatinib Drug Info [14] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia
Mutation Info	Missense: E453A
Drugs	Drug Name Imatinib Drug Info [14], [24] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia
Mutation Info	Missense: E453D
Drugs	Drug Name Imatinib Drug Info [2] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia Mutation Prevalence 1 out of 53 patients
Mutation Info	Missense: E453G
Drugs	Drug Name Imatinib Drug Info [14], [28] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia
Mutation Info	Missense: E453K
Drugs	Drug Name Imatinib Drug Info [1], [2], [14] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia Mutation Prevalence 1 out of 94 patients
Mutation Info	Missense: E453L
Drugs	Drug Name Imatinib Drug Info [19] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia
Mutation Info	Missense: E453V
Drugs	Drug Name Imatinib Drug Info [14] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia
Mutation Info	Missense: E459A
Drugs	Drug Name Imatinib Drug Info [14] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia
Mutation Info	Missense: E459G
Drugs	Drug Name Imatinib Drug Info [1] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia Mutation Prevalence 2 out of 94 patients
Mutation Info	Missense: E459K
Drugs	Drug Name Imatinib Drug Info [1] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia Mutation Prevalence 2 out of 94 patients
Mutation Info	Missense: E459Q
Drugs	Drug Name Imatinib Drug Info [1] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia Mutation Prevalence 1 out of 94 patients
Mutation Info	Missense: E459V
Drugs	Drug Name Imatinib Drug Info [14] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia
Mutation Info	Missense: E494G
Drugs	Drug Name Imatinib Drug Info [15] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia
Mutation Info	Missense: E507G
Drugs	Drug Name Imatinib Drug Info [14] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia
Mutation Info	Missense: F311I
Drugs	Drug Name Imatinib Drug Info [1] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia Mutation Prevalence 2 out of 94 patients
Mutation Info	Missense: F311L
Drugs	Drug Name Imatinib Drug Info [7] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia Mutation Prevalence 38 out of 45 patients
	Drug Name Type I TKIs Drug Info [42]
Mutation Info	Missense: F317C
Drugs	Drug Name Imatinib Drug Info [14], [17] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia
	Drug Name Dasatinib Drug Info [14] Targeted Disease Leukemia
Mutation Info	Missense: F317I
Drugs	Drug Name Imatinib Drug Info [14], [17] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia
	Drug Name Dasatinib Drug Info [14] Targeted Disease Leukemia
Mutation Info	Missense: F317L
Drugs	Drug Name Imatinib Drug Info [1] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia Mutation Prevalence 9 out of 94 patients
	Drug Name Dasatinib Drug Info [5] Targeted Disease Leukemia Mutation Prevalence 4 out of 60 patients
	Drug Name Type I TKIs Drug Info [41], [42], [43]
Mutation Info	Missense: F317R
Drugs	Drug Name Dasatinib Drug Info [39] Targeted Disease Leukemia
Mutation Info	Missense: F317V
Drugs	Drug Name Imatinib Drug Info [8], [14], [17] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia Mutation Prevalence 1 out of 40 patients
	Drug Name Dasatinib Drug Info [14] Targeted Disease Leukemia
Mutation Info	Missense: F359*
Drugs	Drug Name Imatinib Drug Info [19] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia
Mutation Info	Missense: F359?
Drugs	Drug Name Imatinib Drug Info [19] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia
Mutation Info	Missense: F359A
Drugs	Drug Name Imatinib Drug Info [11] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia Mutation Prevalence 16 out of 49 patients in all ABL mutations
Mutation Info	Missense: F359C
Drugs	Drug Name Imatinib Drug Info [1] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia Mutation Prevalence 2 out of 94 patients
	Drug Name Nilotinib Drug Info [20], [14] Targeted Disease Leukemia Mutation Prevalence 2 out of 21 patients
Mutation Info	Missense: F359I
Drugs	Drug Name Imatinib Drug Info [2] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia Mutation Prevalence 2 out of 53 patients
	Drug Name Nilotinib Drug Info [14] Targeted Disease Leukemia
	Drug Name Dasatinib Drug Info [35] Targeted Disease Leukemia
	Drug Name Bosutinib Drug Info [39] Targeted Disease Chronic Myeloid Leukaemia
	Drug Name Type I TKIs Drug Info [42]
Mutation Info	Missense: F359L
Drugs	Drug Name Imatinib Drug Info [14] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia
Mutation Info	Missense: F359V
Drugs	Drug Name Imatinib Drug Info [2] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia Mutation Prevalence 4 out of 53 patients
	Drug Name Nilotinib Drug Info [14] Targeted Disease Leukemia
	Drug Name Dasatinib Drug Info [37] Targeted Disease Leukemia
	Drug Name Bosutinib Drug Info [33] Targeted Disease Chronic Myeloid Leukaemia
	Drug Name Type I TKIs Drug Info [41]
Mutation Info	Missense: F382L
Drugs	Drug Name Imatinib Drug Info [18], [2], [14] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia Mutation Prevalence 1 out of 53 patients
Mutation Info	Missense: F486S
Drugs	Drug Name Imatinib Drug Info [2] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia Mutation Prevalence 3 out of 53 patients
Mutation Info	Missense: G250E
Drugs	Drug Name Imatinib Drug Info [6] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia Mutation Prevalence 6 out of 36 patients
	Drug Name Nilotinib Drug Info [33] Targeted Disease Leukemia
	Drug Name Dasatinib Drug Info [35], [36], [38] Targeted Disease Leukemia
	Drug Name Type I TKIs Drug Info [41], [42], [43]
Mutation Info	Missense: G250R
Drugs	Drug Name Imatinib Drug Info [14] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia
Mutation Info	Missense: G251D
Drugs	Drug Name Imatinib Drug Info [2] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia Mutation Prevalence 1 out of 53 patients
Mutation Info	Missense: G251E
Drugs	Drug Name Imatinib Drug Info [21] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia Mutation Prevalence 1 out of 125 patients
Mutation Info	Missense: G398R
Drugs	Drug Name Imatinib Drug Info [40] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia Mutation Prevalence 33% of the patients
Mutation Info	Missense: H396A
Drugs	Drug Name Imatinib Drug Info [14] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia
Mutation Info	Missense: H396P
Drugs	Drug Name Imatinib Drug Info [2] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia Mutation Prevalence 1 out of 53 patients
Mutation Info	Missense: H396R
Drugs	Drug Name Imatinib Drug Info [1] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia Mutation Prevalence 3 out of 94 patients
	Drug Name Nilotinib Drug Info [27] Targeted Disease Leukemia
	Drug Name Type I TKIs Drug Info [42]
Mutation Info	Missense: I242T
Drugs	Drug Name Imatinib Drug Info [14] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia
Mutation Info	Missense: I293V
Drugs	Drug Name Imatinib Drug Info [14] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia
Mutation Info	Missense: I418S
Drugs	Drug Name Imatinib Drug Info [14] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia
Mutation Info	Missense: I418V
Drugs	Drug Name Imatinib Drug Info [2], [19], [14] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia Mutation Prevalence 1 out of 53 patients
Mutation Info	Missense: K247R
Drugs	Drug Name Imatinib Drug Info [14] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia
Mutation Info	Missense: K294 > RGG
Drugs	Drug Name Imatinib Drug Info [38] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia
Mutation Info	Missense: K378R
Drugs	Drug Name Imatinib Drug Info [15] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia
Mutation Info	Missense: K419E
Drugs	Drug Name Imatinib Drug Info [27] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia
Mutation Info	Missense: L248R
Drugs	Drug Name Bosutinib Drug Info [39] Targeted Disease Chronic Myeloid Leukaemia
Mutation Info	Missense: L248V
Drugs	Drug Name Imatinib Drug Info [9] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia Mutation Prevalence 27 out of 144 patients
Mutation Info	Missense: L273M
Drugs	Drug Name Imatinib Drug Info [2], [22], [14] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia Mutation Prevalence 1 out of 53 patients
	Drug Name Dasatinib Drug Info [36] Targeted Disease Leukemia
Mutation Info	Missense: L298V
Drugs	Drug Name Imatinib Drug Info [6] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia Mutation Prevalence 2 out of 36 patients
Mutation Info	Missense: L324Q
Drugs	Drug Name Imatinib Drug Info [14], [26] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia
Mutation Info	Missense: L340L
Drugs	Drug Name Imatinib Drug Info [7] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia Mutation Prevalence 38 out of 45 patients
Mutation Info	Missense: L364I
Drugs	Drug Name Imatinib Drug Info [1] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia Mutation Prevalence 1 out of 94 patients
Mutation Info	Missense: L370P
Drugs	Drug Name Imatinib Drug Info [14] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia
Mutation Info	Missense: L384M
Drugs	Drug Name Imatinib Drug Info [13] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia Mutation Prevalence 1 out of 4 patients
	Drug Name Type I TKIs Drug Info [42]
Mutation Info	Missense: L387F
Drugs	Drug Name Imatinib Drug Info [14], [24] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia
Mutation Info	Missense: L387M
Drugs	Drug Name Imatinib Drug Info [8] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia Mutation Prevalence 3 out of 40 patients
	Drug Name Type I TKIs Drug Info [41]
Mutation Info	Missense: L387V
Drugs	Drug Name Imatinib Drug Info [14] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia
Mutation Info	Missense: M237V
Drugs	Drug Name Imatinib Drug Info [14] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia
Mutation Info	Missense: M244V
Drugs	Drug Name Imatinib Drug Info [2] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia Mutation Prevalence 8 out of 53 patients
	Drug Name Type I TKIs Drug Info [41], [42]
Mutation Info	Missense: M343T
Drugs	Drug Name Imatinib Drug Info [18], [14] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia
Mutation Info	Missense: M351K
Drugs	Drug Name Imatinib Drug Info [15] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia
Mutation Info	Missense: M351T
Drugs	Drug Name Imatinib Drug Info [3] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia Mutation Prevalence 7 out of 77 patients
	Drug Name Nilotinib Drug Info [32] Targeted Disease Leukemia
	Drug Name Bosutinib Drug Info [33] Targeted Disease Chronic Myeloid Leukaemia
Mutation Info	Missense: M388L
Drugs	Drug Name Imatinib Drug Info [1], [2], [14] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia Mutation Prevalence 1 out of 94 patients
	Drug Name Type I TKIs Drug Info [41]
Mutation Info	Missense: M472I
Drugs	Drug Name Imatinib Drug Info [14] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia
Mutation Info	Missense: N368S
Drugs	Drug Name Imatinib Drug Info [21] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia Mutation Prevalence 1 out of 125 patients
Mutation Info	Missense: N374Y
Drugs	Drug Name Imatinib Drug Info [30] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia
Mutation Info	Missense: P480L
Drugs	Drug Name Imatinib Drug Info [25], [14] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia Mutation Prevalence 1 out of 55 patients
Mutation Info	Missense: Q252E
Drugs	Drug Name Imatinib Drug Info [29] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia Mutation Prevalence 30% of the patients
Mutation Info	Missense: Q252H
Drugs	Drug Name Imatinib Drug Info [10] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia Mutation Prevalence 23 out of 66 patients in all ABL mutations
	Drug Name Type I TKIs Drug Info [42]
Mutation Info	Missense: Q252K
Drugs	Drug Name Imatinib Drug Info [20] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia Mutation Prevalence 1 out of 21 patients
Mutation Info	Missense: Q252R
Drugs	Drug Name Imatinib Drug Info [18], [14] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia
Mutation Info	Missense: R220H
Drugs	Drug Name Type I TKIs Drug Info [42]
Mutation Info	Missense: R328M
Drugs	Drug Name Imatinib Drug Info [2] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia Mutation Prevalence 1 out of 53 patients
Mutation Info	Missense: S417F
Drugs	Drug Name Imatinib Drug Info [14] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia
Mutation Info	Missense: S417Y
Drugs	Drug Name Imatinib Drug Info [7] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia Mutation Prevalence 38 out of 45 patients
Mutation Info	Missense: S438C
Drugs	Drug Name Imatinib Drug Info [14], [15], [24] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia
Mutation Info	Missense: T277A
Drugs	Drug Name Imatinib Drug Info [14], [15], [7] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia Mutation Prevalence 38 out of 45 patients
Mutation Info	Missense: T315A
Drugs	Drug Name Dasatinib Drug Info [14], [39] Targeted Disease Leukemia
	Drug Name Imatinib Drug Info [17] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia
Mutation Info	Missense: T315I
Drugs	Drug Name Imatinib Drug Info [1] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia Mutation Prevalence 9 out of 94 patients
	Drug Name Nilotinib Drug Info [31] Targeted Disease Leukemia
	Drug Name Dasatinib Drug Info [34] Targeted Disease Leukemia Mutation Prevalence 12 out of 17 patients
	Drug Name Bosutinib Drug Info [14] Targeted Disease Chronic Myeloid Leukaemia
	Drug Name Type I TKIs Drug Info [41], [42], [43]
	Drug Name Nilotinib + Dasatinib Drug Info [14]
Mutation Info	Missense: T315N
Drugs	Drug Name Imatinib Drug Info [11] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia Mutation Prevalence 16 out of 49 patients in all ABL mutations
Mutation Info	Missense: T315V
Drugs	Drug Name Nilotinib Drug Info [39] Targeted Disease Leukemia
Mutation Info	Missense: T495R
Drugs	Drug Name Dasatinib Drug Info [35] Targeted Disease Leukemia
Mutation Info	Missense: V256L
Drugs	Drug Name Imatinib Drug Info [15] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia
Mutation Info	Missense: V280A
Drugs	Drug Name Imatinib Drug Info [14] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia
Mutation Info	Missense: V289A
Drugs	Drug Name Imatinib Drug Info [14] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia
	Drug Name Type I TKIs Drug Info [42]
Mutation Info	Missense: V289F
Drugs	Drug Name Imatinib Drug Info [6], [23], [21] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia Mutation Prevalence 1 out of 40 patients
Mutation Info	Missense: V289I
Drugs	Drug Name Imatinib Drug Info [14] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia
Mutation Info	Missense: V299L
Drugs	Drug Name Imatinib Drug Info [14], [15], [16], [17] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia
	Drug Name Dasatinib Drug Info [14], [16], [35], [36], [37] Targeted Disease Leukemia
	Drug Name Bosutinib Drug Info [16] Targeted Disease Chronic Myeloid Leukaemia
	Drug Name Type I TKIs Drug Info [42], [43]
Mutation Info	Missense: V371A
Drugs	Drug Name Imatinib Drug Info [14] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia
Mutation Info	Missense: V379I
Drugs	Drug Name Imatinib Drug Info [7] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia Mutation Prevalence 38 out of 45 patients
	Drug Name Dasatinib Drug Info [36] Targeted Disease Leukemia
Mutation Info	Missense: W261L
Drugs	Drug Name Imatinib Drug Info [14] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia
Mutation Info	Missense: Y253F
Drugs	Drug Name Imatinib Drug Info [2] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia Mutation Prevalence 3 out of 53 patients
	Drug Name Dasatinib Drug Info [36] Targeted Disease Leukemia
Mutation Info	Missense: Y253H
Drugs	Drug Name Imatinib Drug Info [5] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia Mutation Prevalence 6 out of 60 patients
	Drug Name Nilotinib Drug Info [14], [27] Targeted Disease Leukemia
	Drug Name Dasatinib Drug Info [36], [38], [33] Targeted Disease Leukemia
	Drug Name Type I TKIs Drug Info [41]
Mutation Info	Missense: Y320C
Drugs	Drug Name Imatinib Drug Info [14], [15] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia
Mutation Info	Missense: Y342H
Drugs	Drug Name Imatinib Drug Info [14] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia
Mutation Info	Missense: Y353H
Drugs	Drug Name Dasatinib Drug Info [36] Targeted Disease Leukemia
	Drug Name Imatinib Drug Info [6] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia Mutation Prevalence 4 out of 36 patients
Mutation Info	Missense: Y393C
Drugs	Drug Name Imatinib Drug Info [14] Targeted Disease Gastrointestinal Stromal Tumor; Leukemia
References
REF 1	Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations. Blood. 2009 Sep 3;114(10):2037-43.
REF 2	Determining the rise in BCR-ABL RNA that optimally predicts a kinase domain mutation in patients with chronic myeloid leukemia on imatinib. Blood. 2009 Sep 24;114(13):2598-605.
REF 3	BCR-ABL isoforms associated with intrinsic or acquired resistance to imatinib: more heterogeneous than just ABL kinase domain point mutations Med Oncol. 2012 Mar;29(1):219-26.
REF 4	Characterization of the rpsL and rrs genes of streptomycin-resistant clinical isolates of Mycobacterium tuberculosis in Japan. J Appl Microbiol. 1997 Nov;83(5):634-40.
REF 5	BCR-ABL1 mutations in patients with imatinib-resistant Philadelphia chromosome-positive leukemia by use of the PCR-Invader assay. Leuk Res. 2011 May;35(5):598-603.
REF 6	Clinical outcome of chronic myeloid leukemia imatinib-resistant patients: do BCR-ABL kinase domain mutations affect patient survival First multicenter Argentinean study. Leuk Lymphoma. 2011 Sep;52(9):1720-6.
REF 7	Frequency of ABL gene mutations in chronic myeloid leukemia patients resistant to imatinib and results of treatment switch to second-generation tyrosine kinase inhibitors. Med Clin (Barc). 2013 Aug 4;141(3):95-9.
REF 8	Mutations in ABL kinase domain are associated with inferior progression-free survival. Leuk Lymphoma. 2010 Jun;51(6):1072-8.
REF 9	Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in ... Blood. 2003 Jul 1;102(1):276-83.
REF 10	Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia. 2002 Nov;16(11):2190-6.
REF 11	High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib. Hematol J. 2004;5(1):55-60.
REF 12	Rapid and sensitive allele-specific (AS)-RT-PCR assay for detection of T315I mutation in chronic myeloid leukemia patients treated with tyrosine-kinase inhibitors. Clin Exp Med. 2011 Mar;11(1):55-9.
REF 13	The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov. 2014 Jan;4(1):94-109.
REF 14	BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood. 2011 Aug 4;118(5):1208-15.
REF 15	Impact of BCR-ABL mutations on response to dasatinib after imatinib failure in elderly patients with chronic-phase chronic myeloid leukemia. Ann Hematol. 2013 Jan;92(2):179-83.
REF 16	Characteristics and outcomes of patients with V299L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors. Blood. 2012 Oct 18;120(16):3382-3.
REF 17	BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships. Blood. 2013 Jan 17;121(3):489-98.
REF 18	Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell. 2002 Aug;2(2):117-25.
REF 19	Characteristics of BCR-ABL kinase domain point mutations in Chinese imatinib-resistant chronic myeloid leukemia patients. Ann Hematol. 2011 Jan;90(1):47-52.
REF 20	Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations. Blood. 2011 Mar 31;117(13):3641-7.
REF 21	BCR-ABL kinase domain mutations, including 2 novel mutations in imatinib resistant Malaysian chronic myeloid leukemia patients-Frequency and clinical outcome. Leuk Res. 2014 Apr;38(4):454-9.
REF 22	Spectrum of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia from India with suspected resistance to imatinib-mutations are rare and have different distributions. Leuk Lymphoma. 2009 Dec;50(12):2092-5.
REF 23	Contribution of BCR-ABL kinase domain mutations to imatinib mesylate resistance in Philadelphia chromosome positive Malaysian chronic myeloid leukemia patients. Hematol Rep. 2012 Nov 19;4(4):e23.
REF 24	Detection of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on imatinib. Hematology. 2013 Nov;18(6):328-33.
REF 25	Dynamic change of T315I BCR-ABL kinase domain mutation in Korean chronic myeloid leukaemia patients during treatment with Abl tyrosine kinase inhibitors. Hematol Oncol. 2010 Jun;28(2):82-8.
REF 26	Increased genomic instability may contribute to the development of kinase domain mutations in chronic myeloid leukemia. Int J Hematol. 2014 Dec;100(6):567-74.
REF 27	Role of treatment in the appearance and selection of BCR-ABL1 kinase domain mutations. Mol Diagn Ther. 2012 Aug 1;16(4):251-9.
REF 28	BCR-ABL1 kinase domain mutations may persist at very low levels for many years and lead to subsequent TKI resistance. Br J Cancer. 2013 Sep 17;109(6):1593-8.
REF 29	Evidence of ABL-kinase domain mutations in highly purified primitive stem cell populations of patients with chronic myelogenous leukemia. Biochem Biophys Res Commun. 2004 Oct 22;323(3):728-30.
REF 30	Kinase domain mutations and responses to dose escalation in chronic myeloid leukemia resistant to standard dose imatinib mesylate. Leuk Lymphoma. 2010 Jan;51(1):79-84.
REF 31	Analysis of mutations in the BCR-ABL1 kinase domain, using direct sequencing: detection of the T315I mutation in bone marrow CD34+ cells of a patient with chronic myelogenous leukemia 6 months prior to its emergence in peripheral blood. Mol Diagn Ther. 2012 Jun 1;16(3):163-6.
REF 32	Sequential development of mutant clones in an imatinib resistant chronic myeloid leukaemia patient following sequential treatment with multiple tyrosine kinase inhibitors: an emerging problem Cancer Chemother Pharmacol. 2009 Jun;64(1):195-7.
REF 33	Outcome of patients with chronic myeloid leukemia with multiple ABL1 kinase domain mutations receiving tyrosine kinase inhibitor therapy. Haematologica. 2011 Jun;96(6):918-21.
REF 34	Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 2011 Dec 15;118(25):6521-8.
REF 35	Complexity of BCR-ABL kinase domain mutations during the course of therapy with tyrosine kinase inhibitors in chronic myeloid leukemia. Am J Hematol. 2009 Apr;84(4):256-7.
REF 36	Longitudinal studies of SRC family kinases in imatinib- and dasatinib-resistant chronic myelogenous leukemia patients. Leuk Res. 2011 Jan;35(1):38-43.
REF 37	Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer. 2015 Dec 1;121(23):4158-64.
REF 38	A novel insertion mutation of K294RGG within BCR-ABL kinase domain confers imatinib resistance: sequential analysis of the clonal evolution in a patient with chronic myeloid leukemia in blast crisis. Int J Hematol. 2011 Feb;93(2):237-42.
REF 39	Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors. Am J Hematol. 2012 Nov;87(11):E125-8.
REF 40	Incidence and clinical importance of BCR-ABL1 mutations in Iranian patients with chronic myeloid leukemia on imatinib. J Hum Genet. 2015 May;60(5):253-8.
REF 41	Use of direct sequencing for detection of mutations in the BCR-ABL kinase domain in Slovak patients with chronic myeloid leukemia. Neoplasma. 2011;58(6):548-53.
REF 42	[ABL domain kinase point mutations as a cause of resistance to therapy of patients with chronic myeloid leukemia with tyrosine kinase inhibitors. S... Przegl Lek. 2011;68(5):253-7.
REF 43	Early detection and quantification of mutations in the tyrosine kinase domain of chimerical BCR-ABL1 gene combining high-resolution melting analysis and mutant-allele specific quantitative polymerase chain reaction. Leuk Lymphoma. 2013 Mar;54(3):598-606.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.